Theres a shelf offering for 350million. I have a feeling dilution in the future. Ive been holding since for a while and was sent an email to vote to increase OS from 120mil to 400mil.
ALL good buddy PDSB has a shelf offering for a 100 million in June 2020. They haven't issued more shares to the float yet! They do these kind of things for strategic reasons & flexibility usually if there are people looking to acquire a company or be acquired. Also if HEPA did do another offering it wouldn't be for a while. This company has so much going for it's fabulous. The Shelf's are an insurance policy.
Those who don't know the most basic stuff, like the difference between authorized shares and issued shares, really shouldn't be trading stocks at all, but then they won't be around for very long, so!
There's almost no retail to wrest shares from. There are 76m shares out. >95% institutional ownership. No filings were submitted for ~70% of the 64m shares bought at the November and February offerings, meaning the vast majority was concealed. Before institutions bought 64m shares at those offerings, there were 12m shares out, with 3m in the public float. So, direct holders had ~9m shares of that, and tutes got 64m at the offerings, which possibly left ~3m for retail then. The only reason there had been any volume at all here was because the effective float had been bloated by abusive naked short selling.
We talk about all the indications for which CRV431 appears to have tremendous potential, and some of them have enormous global treatment markets, including NASH itself at tens of billions of dollars and with a huge CAGR, but let's not lose sight of the fact that there is currently no approved treatment for NASH, so with a fat score in the 225mg cohort, the house could soon be rockin'!!
By the way, some competitors' greatly inferior NASH drugs are being valued in the billions. Just a 1B MC for Hepion makes for $13.12 a share, and CRV431 is going to eventually treat many other indications, some with treatment markets in the many tens of billions.
To put into perspective HEPA NASH market is 10x greater than what PDSB is trying to capture with their Cancer & Covid Indications. There is so much more coming down the pipeline with HEPA. Know what you own add at these levels and you will be rewarded greatly imo
News 
Market Data 
Discover 
